CEBPA antibody

Catalog No. ABIN2664083

The Mouse Monoclonal anti-CEBPA antibody (Clone 16C12B70) (ABIN2664083) specifically detects CEBPA in FACS and IF. The antibody is reactive with Human samples.

Quick Overview for CEBPA antibody (ABIN2664083)

Target: CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CEBPA antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: 16C12B70

Product Details anti-CEBPA Antibody

Cross-Reactivity: Mouse (Murine)

Cross-Reactivity (Details): weakly cross-reacts with mouse

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CEBPA

Target: CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))

Alternative Name: C/EBPalpha

Background: The CCAAT-enhancer binding proteins (C/EBP) are members of the basic region/leucine zipper (bZIP) transcription factors, that bind to the consensus CCAAT sequence in DNA. C/EBPα is expressed in two isoforms: p42 and p30 by ultilizing different translational start codons. The C/EBPα p30 isoform has little to no transactivating activity and acts as an inhibitor. C/EBPα regulates expression of various myeloid-specific genes and is required for myeloid differentiation. C/EBPα has been found to play a key role in adipogenesis, since inhibition of C/EBPα blocks adipocyte differentiation. C/EBPα also regulates cell cycle progression through interactions with cyclin-dependent kinases (CDK) and by inducing the expression of CDK inhibitor p21. Mutations in the C/EBPα gene are associated with the development of acute myeloid leukemia.

Pathways: Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation